HighVista Strategies LLC Purchases New Shares in ADMA Biologics Inc $ADMA

HighVista Strategies LLC bought a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA) in the third quarter, Holdings Channel reports. The fund bought 95,112 shares of the biotechnology company’s stock, valued at approximately $1,394,000.

Several other institutional investors and hedge funds have also modified their holdings of ADMA. State Street Corp increased its position in ADMA Biologics by 5.6% during the second quarter. State Street Corp now owns 12,078,505 shares of the biotechnology company’s stock worth $219,950,000 after acquiring an additional 637,727 shares during the period. Geode Capital Management LLC boosted its holdings in ADMA Biologics by 4.3% in the 2nd quarter. Geode Capital Management LLC now owns 5,913,121 shares of the biotechnology company’s stock valued at $107,691,000 after purchasing an additional 245,309 shares during the period. Westfield Capital Management Co. LP bought a new stake in ADMA Biologics in the 3rd quarter valued at about $74,866,000. Dimensional Fund Advisors LP grew its position in shares of ADMA Biologics by 0.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 4,798,274 shares of the biotechnology company’s stock worth $70,343,000 after purchasing an additional 35,199 shares in the last quarter. Finally, American Century Companies Inc. increased its holdings in shares of ADMA Biologics by 1.8% during the third quarter. American Century Companies Inc. now owns 4,695,923 shares of the biotechnology company’s stock worth $68,842,000 after purchasing an additional 84,934 shares during the period. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other ADMA Biologics news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the firm’s stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the sale, the chief operating officer owned 466,600 shares in the company, valued at $7,292,958. This trade represents a 2.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Steve Elms bought 7,000 shares of the firm’s stock in a transaction on Thursday, March 5th. The shares were bought at an average cost of $15.67 per share, for a total transaction of $109,690.00. Following the purchase, the director owned 2,038,730 shares of the company’s stock, valued at approximately $31,946,899.10. The trade was a 0.34% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 3.70% of the company’s stock.

ADMA Biologics Stock Up 1.1%

NASDAQ ADMA opened at $15.15 on Monday. The business has a fifty day moving average price of $16.63 and a two-hundred day moving average price of $16.70. The stock has a market capitalization of $3.61 billion, a PE ratio of 25.25 and a beta of 0.51. ADMA Biologics Inc has a fifty-two week low of $13.76 and a fifty-two week high of $25.67. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The company had revenue of $139.16 million for the quarter, compared to analyst estimates of $139.80 million. During the same quarter last year, the company posted $0.46 EPS. The company’s revenue for the quarter was up 18.4% compared to the same quarter last year. Equities analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on ADMA shares. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Wall Street Zen raised ADMA Biologics from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Finally, Zacks Research raised shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 2nd. Two research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $32.00.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.